Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 15, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-022-01341-0
Keywords
Triple-negative breast cancer; Targeted therapy; Immunotherapy; Combination therapy
Categories
Funding
- National Natural Science Foundation of China [81974074, 81570537, 82172654]
- Hunan Provincial Science and Technology Department [2018RS3026, 2021RC4012]
- Russian Science Foundation [22-25-00868]
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available